Quick Answer: The selected primary records do not establish an optimal human morning, pre-workout or post-workout schedule for IGF-1 LR3. They examine chemical structure, binding proteins, animal clearance and analytical detection. Those measurements cannot be converted into a proven training window.
On this page
- Which IGF molecule was studied?
- What clearance studies found
- Detection time versus half-life
- The human free-IGF record
- Ratios that do not mean the same thing
- Frequently asked questions
IGF-I, R3 and Long R3 are different preparations
The 1995 folding study tested substitutions at positions 3 and 9 and a thirteen-amino-acid N-terminal extension. Long-[Arg3]IGF-I combines an extension with an amino-acid substitution. A study of recombinant human IGF-I should not be relabeled as a human LR3 study.
| Record | Molecule and model | What was measured |
|---|---|---|
| 1995 folding study | IGF-I analogues and laboratory assays | Folding isomers, binding-protein association and biological properties |
| 1993 binding/clearance comparison | IGF-I versus LR3IGF-I; cultured myoblasts and rats | Affinity, growth response and plasma removal |
| 2021 analytical detection study | Analogues administered to rats; human serum spiking and whole-blood incubation | Detectability of parent compounds and degradation products |
| 1999 human free-IGF study | Recombinant human IGF-I in five healthy men | Free and total IGF-I concentrations and disappearance of the free fraction |
Reduced binding does not necessarily mean slower removal
The 1993 comparison reports approximately 1,000-fold higher IGF-I affinity than LR3IGF-I for the specified binding proteins and preparations. LR3 showed greater biological potency in the myoblast assays and rat growth measurements, but was removed from rat plasma more rapidly than IGF-I. Binding proteins can affect retention in the circulation.
From the FormBlends catalog
IGF-1 LR3
Extended-action insulin-like growth factor for muscle growth · From $119/mo · compounded by a licensed 503A pharmacy, dispensed only after provider review.
Learn about IGF-1 LR3 →These observations do not support the earlier page's claim that LR3 automatically supplies a twenty-to-thirty-hour human exposure window. The animal clearance comparison and a human post-workout timing trial would answer different questions.
A four-hour detection observation is not a four-hour half-life
The 2021 study evaluated detection after a single 100 micrograms/kg intramuscular administration in rats. The reported unchanged LongR3 compound disappeared rapidly after four hours, while a named degradation product was detectable up to sixteen hours. These were analytical observations, not measurements of exercise-related muscle growth.
The study also used human serum spiking and whole-blood incubation. Those procedures do not mean LR3 was administered to human volunteers. Detecting a degradation product does not demonstrate ongoing receptor activity of the unchanged molecule.
| Term | What is needed to interpret it | What it does not establish alone |
|---|---|---|
| Detection window | Specimen, assay sensitivity, compound or metabolite and sampling times | A half-life or training benefit |
| Plasma half-life | A concentration-time model for the named measured fraction | A universal dose interval |
| Biological-effect duration | A specified endpoint measured over time | Continued presence of unchanged compound |
Why a real human half-life still cannot answer the LR3 question
The five-man crossover study administered recombinant human IGF-I by seventy-five-minute infusion. Its high-dose condition yielded an apparent free-IGF-I half-life of 14.4 minutes. The measured free fraction, administered molecule and intravenous protocol must remain attached to that number.
Converting 14.4 minutes to hours gives 14.4 / 60 = 0.24 hours. A value of twenty-four hours would be one hundred times larger. This is a unit check, not evidence that LR3 has either value. A total-IGF concentration and a free-IGF concentration are also different measurements.
Binding, assay potency and growth are separate ratios
| Comparison | Approximate ratio | Interpretation |
|---|---|---|
| IGF-I versus LR3 affinity for specified binding-protein preparations | 1,000-fold | Binding association |
| LR3 versus IGF-I potency in cultured L6 myoblasts | 5-10-fold | Cell-assay response |
| LR3 versus IGF-I potency in rat growth measurements | 6-fold | Animal growth endpoint |
A 1,000-fold affinity comparison is not a 1,000-fold muscle-gain result. Neither the assay ratio nor the animal growth ratio supplies a human timing recommendation.
Existing risk context
1. Hypoglycemia is the acute serious risk. The cited studies do not establish a safe LR3 amount, a 40-50 microgram threshold or a fixed 60-minute risk limit. Symptoms progress from shakiness and sweating to confusion and loss of consciousness. Always have fast-acting carbohydrates (glucose tablets, juice) immediately available after any injection.
2. Mitogenic risk is real and long-term effects are unknown. IGF-1R activation is a known driver of cell proliferation via the MAPK pathway. Epidemiological data consistently links higher endogenous IGF-1 levels with increased risk of colorectal, prostate, and breast cancers. Whether short-cycle exogenous LR3 use in healthy adults causes clinical harm is genuinely unknown, not proven safe. The absence of evidence is not evidence of absence.
3. Purity and contamination risk from research chemical suppliers is not theoretical. Independently published analyses of peptide products from online research chemical sources have documented contamination, incorrect concentrations, and sterility failures. Injecting a contaminated peptide carries infection risk including abscess, bacteremia, and endocarditis. This risk has nothing to do with IGF-1 LR3 pharmacology; it is a supply chain problem that no timing protocol can mitigate.
Frequently asked questions
Is post-workout the proven best time?
The named records do not compare human pre-workout, post-workout and morning administration against shared outcomes.
Does “Long” establish a long human half-life?
No. It identifies the molecular extension. A human concentration-time study of that molecule is needed for a human half-life claim.
Does an experiment with human serum count as a human dosing trial?
No. Spiking a specimen or incubating a compound in blood is a laboratory procedure.
Primary references
- IGF-I analogue folding, 1995
- Binding proteins, plasma clearance and biological activity, 1993
- Analogue detection study, 2021
- Human free-IGF-I pharmacokinetics, 1999
Footer Disclaimers
Related peptide guides
Ready when you are
IGF-1 LR3
Extended-action insulin-like growth factor for muscle growth · From $119/mo · compounded by a licensed 503A pharmacy, dispensed only after provider review.
Learn about IGF-1 LR3 →